Sugi Predict

Sugi Predict / Compounds / SCHEMBL3889326

SCHEMBL3889326

SCHEMBL3889326

O=S(=O)(OS(=O)(=O)c1ccc(Br)cc1)c1ccc(Br)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 6/20 0.54
▸ PLCG1 P19174 1/20 0.52
▸ CA9 Q16790 5/20 0.48
▸ CA12 O43570 5/20 0.48
▸ MMP2 P08253 4/20 0.48
▸ CA1 P00915 4/20 0.48
▸ MMP1 P03956 1/20 0.48
▸ MMP9 P14780 1/20 0.48
▸ MMP8 P22894 1/20 0.48
▸ MMP13 P45452 1/20 0.48
▸ F2 P00734 3/20 0.43
▸ PRSS1 P07477 3/20 0.43
▸ PRSS2 P07478 3/20 0.43
▸ PRSS3 P35030 3/20 0.43
▸ IDO1 P14902 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ CYP2A6 P11509 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ LMNA P02545 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7781144 0.89 ALDH1A1 (0.54) CA2PLCG1CA9CA12MMP2
SCHEMBL29393881 0.84 CA2 (0.54) CA2PLCG1CA9CA12MMP2
SCHEMBL15176900 0.80 CA2 (0.50) CA2PLCG1CA9CA12MMP2
SCHEMBL15015034 0.80 CA2 (0.50) CA2PLCG1CA9CA12MMP2
SCHEMBL27695450 0.80 CA2 (0.50) CA2PLCG1CA9CA12MMP2
SCHEMBL9720951 0.80 CA2 (0.50) CA2PLCG1CA9CA12MMP2
SCHEMBL17278786 0.80 CA2 (0.50) CA2PLCG1CA9CA12MMP2
SCHEMBL6262857 0.80 CA2 (0.50) CA2PLCG1CA9CA12MMP2
SCHEMBL22632046 0.80 CA2 (0.56) CA2PLCG1CA9CA12MMP2
SCHEMBL16467641 0.80 CA2 (0.50) CA2PLCG1CA9CA12MMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7498431-B2 Process for the preparation of chiral azetidinones FRAMROZE BOMI PATEL 2009-03-03 — — US claimed
US-20070129540-A1 Process for the preparation of chiral azetidinones OPUS ORGANICS PVT LIMITED (IN) 2007-06-07 — — US claimed
US-20260137789-A1 BRUSH PRODRUGS AND USES THEREOF MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2026-05-21 — — US disclosed
US-12478683-B2 Brush prodrugs and uses thereof MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2025-11-25 — — US disclosed
US-12172956-B2 Method for the isomerization of a 3-(Z)-unsaturated carboxylic acid to the 3-(E)-isomer BASF SE (DE) 2024-12-24 — — US disclosed
CN-111741943-B Method for isomerising 3- (Z) -unsaturated carboxylic acids into 3- (E) -isomers 巴斯夫欧洲公司 2024-07-02 — — CN disclosed
CN-114989000-B Process for preparing unsaturated carboxylic acids by carbonylation of allyl alcohol and its acylated products 巴斯夫欧洲公司 2024-05-10 — — CN disclosed
CN-114989000-A Process for preparing unsaturated carboxylic acids by carbonylation of allyl alcohol and acylates thereof 巴斯夫欧洲公司 2022-09-02 — — CN disclosed
EP-4045562-A2 BRUSH PRODRUGS AND USES THEREOF Massachusetts Institute of Technology (US) 2022-08-24 — — EP disclosed
CN-114829447-A Brush prodrug and use thereof 麻省理工学院 2022-07-29 — — CN disclosed
CN-110312701-B Process for preparing unsaturated carboxylic acids by carbonylation of allyl alcohol and acylates thereof 巴斯夫欧洲公司 2022-06-03 — — CN disclosed
EP-0576228-B1 Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates LILLY CO ELI (US) 1999-02-03 — — EP disclosed
EP-0577303-B1 Stereoselective glycosylation process LILLY CO ELI (US) 1997-10-01 — — EP disclosed
EP-0577302-B1 Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates LILLY CO ELI (US) 1997-07-16 — — EP disclosed
EP-0577302-A1 Process for preparing alpha-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl sulfonates ELI LILLY AND COMPANY (US) 1994-01-05 — — EP disclosed
EP-0577303-A1 Stereoselective glycosylation process ELI LILLY AND COMPANY (US) 1994-01-05 — — EP disclosed
EP-0576228-A1 Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates ELI LILLY AND COMPANY (US) 1993-12-29 — — EP disclosed
US-5256798-A Treating beta-anomer ribofuranosyl sulfonate with source of conjugate anion ELI LILLY AND COMPANY (US) 1993-10-26 — — US disclosed
US-5252756-A Process for preparing beta-anomer enriched 2-deoxy-2,2-difluoro-D-ribofuranosyl-arylsulfonates ELI LILLY AND COMPANY (US) 1993-10-12 — — US disclosed
US-4115058-A BLEACHES, DETERGENTS FMC CORPORATION (US) 1978-09-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137789-A1 BRUSH PRODRUGS AND USES THEREOF ABCB11, SLC10A2, CES2 CA2 168/4885PLCG1 1440/4885CA9 162/4885
US-12478683-B2 Brush prodrugs and uses thereof ABCB11, SI, ABCB1 CA2 818/4885PLCG1 1345/4885CA9 244/4885
US-12172956-B2 Method for the isomerization of a 3-(Z)-unsaturated carboxylic acid to the 3-(E)-isomer HCAR2, HCAR1, AKR1C3 CA2 369/4885PLCG1 2393/4885CA9 884/4885
US-20070129540-A1 Process for the preparation of chiral azetidinones CYP1B1, ALDH7A1, CYP3A5 CA2 3896/4885PLCG1 3523/4885CA9 820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.